MedTrace Logo

Absolute Bioavailability Study With Bexagliflozin

NCT03417076 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2019-09-30

No results posted yet for this study

Summary

The purpose of this study is to determine the absolute bioavailability of bexagliflozin following a single oral dose co-administered with an intravenous dose.

Conditions

Interventions

DRUG

Bexagliflozin

Bexagliflozin tablets, 20 mg, and bexagliflozin by IV

Sponsors & Collaborators

  • Theracos

    lead INDUSTRY

Principal Investigators

  • Mason Freeman, M.D. · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2018-09-16
Completion
2018-09-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03417076 on ClinicalTrials.gov